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Cytomegalovirus (CMV) has a series of attributes that makes it attractive as a vector for gene transfer. In healthy individuals the course of the CMV infection is usually asymptomatic. 1 Vaccination experiments with attenuated CMV strains were without severe side-effects even in renal transplant patients who received immunosuppressive treatment. 2, 3 A wide range of cell types can be infected with CMV during acute infection 4 suggesting that a CMV vector can be used for gene transfer into these cells. Especially attractive is the persistence of the CMV genome in hematopoietic progenitor cells during the latent phase of infection. [5] [6] [7] Thus, a CMV vector may be used for gene therapy of congenital and acquired diseases of the hematopoietic system.
CMV has the largest genome among mammalian DNA viruses, 8 and up to 50% of the encoded proteins may be nonessential for replication of the virus in cell culture. A CMV vector will therefore offer a unique cloning capacity and the possibility of expressing several transgenes or will allow the transfer of large genetic units including their regulatory sequences. Expression of immune evasion genes Correspondence: Dr M Messerle, Max von Pettenkofer-Institut, Genzentrum, Ludwig-Maximilians-Universität München, Feodor-Lynen-Stra␤e 25, D-81377 München, Germany allows the virus to interfere with the immune response of the host. 9 Utilization of these genes by gene therapy vectors will protect transduced cells from the immune response and will extend their survival in vivo.
A prerequisite for construction of gene transfer vectors is that the vector genome can easily and specifically be manipulated in vitro. So far, mutagenesis of CMV has been impeded by its large genome size and the slow replication kinetics in tissue culture. To overcome these limitations we have recently established a new mutagenesis procedure by cloning of the CMV genome as a bacterial artificial chromosome (BAC) in E. coli.
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Here, we report on the construction of a recombinant CMV that expresses the green fluorescence protein (GFP). This recombinant virus will be used to determine the range of cell types that can be targeted with a CMV vector.
Materials and methods
Tissue culture, propagation of CMV and plaque assays were performed as described previously. 11 For FACS analysis human foreskin fibroblasts (HFF) were infected with an MOI of 5 in the presence of cycloheximide (CH; 50 g/ml). Twelve h post infection CH was removed by washing the cells three times with DMEM/5% FCS, and cells were then cultivated for another 6 h. Then, cells were harvested by trypsination and GFP expression was determined by FACS analysis using a FACSCalibur (Becton Dickinson, Biosciences, San Jose, CA, USA).
For construction of the recombination plasmid, a 1.6 kbp NsiI-MluI fragment from plasmid pEGFP-C1 (Clontech, Palo Alto, CA, USA) comprising the EGFP gene was inserted into a pUC19 derivative that already contained a 1.9 kbp AscI-XbaI fragment of the BAC vector pKSO. 10 Then, a 1.9 kbp HincII fragment of the CMV genome (nucleotides 200173 to 202063 of the CMV strain AD169 genome 8 ) was cloned into the resulting plasmid to provide sequences that were required for homologous recombination in E. coli. The complete insert (EGFP gene plus flanking sequences) was transferred as a 5.4 kbp BamHI fragment into the shuttle plasmid pST76K-SacB. 11, 12 Mutagenesis of the CMV BAC plasmid and reconstitution of infectious virus was performed as described recently.
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Results
Generation of a recombinant GFP virus
We decided to generate a recombinant CMV that expresses the green fluorescent protein (GFP) in order to determine the range of cell types that can be targeted with a CMV vector. GFP is a highly versatile marker protein that can easily be detected by immunofluorescence or FACS analysis. Thus, targeting of various cell types by the recombinant CMV can be monitored by following the expression of GFP.
For integration of the GFP gene into the CMV BAC plasmid a recombination plasmid was constructed containing the GFP gene flanked by sequences that are homologous to the parental CMV BAC plasmid pHB5 11 (compare Figure 1) . Homologous recombination between the CMV BAC plasmid and the recombination plasmid was performed in E. coli by following a recently described mutagenesis procedure. 10, 11 This led to the replacement of the viral genes US7 to US11 and the insertion of the GFP gene into the CMV BAC plasmid (Figure 1, bottom line) . Characterization of the CMV GFP BAC plasmid by restriction enzyme analysis confirmed the successful insertion of the GFP gene (data not shown). Transfection of the CMV GFP BAC plasmid into MRC-5 cells led to plaque formation and generation of the recombinant GFP virus. Infected cells showed a bright green staining if examined by fluorescence microscopy (data not shown).
Characterization of the GFP virus
The growth properties of the GFP virus were compared to that of the parental virus to determine whether expression of the GFP marker has any influence on growth of the virus. Human fibroblasts were infected with the GFP virus or the parental strain RVHB5 at an MOI of 0.1 p.f.u./cell. Supernatants of the cultures were harvested at several time points post infection and virus titers were determined by plaque titration (Figure 2a ). The GFP virus displayed a growth kinetics comparable to that of the parental virus. This result indicates that expression of GFP does not interfere with growth of the virus. It also confirms that the replaced viral genes US7 to US11 are not required for replication of CMV in cell culture.
Expression of the GFP marker may also offer the possibility of identifying infected cells by FACS analysis. To test this, HFF cells were either infected with the parental virus or with the GFP virus. Figure 2b shows that cells infected with the GFP virus display a strong green fluor- escence. FACS analysis of mock-infected cells and of cells infected with the parental strain RVHB5 did not show any green fluorescence. FACS sorting may therefore be used to enrich for cells that were transduced with a GFP expressing CMV vector.
Discussion
In this paper we describe the construction and characterization of a recombinant CMV that expresses the GFP marker. Since its discovery a few years ago, GFP has become a unique reporter system in various organisms. 13 It is especially valuable for analysis of vital cells because no fixation or destruction of cells is required to detect GFP. Transcription of the GFP gene in the recombinant CMV is under control of the strong major immediate-early promoter/enhancer of CMV. This results in a strong expression of GFP early in infection. Because of the early expression kinetics, we expect to see fluorescence even if the infection is non-productive or if replication is blocked at a late stage of the replication cycle. Monitoring of cell targeting is, however, dependent on viral gene expression. There is evidence that viral gene expression is very limited in cell types where CMV establishes a latent infection. 7 Additional techniques, eg in situ hybridization or PCR, will be needed to analyze the targeting of such cell types. In general, the GFP marker will be a useful tool to monitor gene transfer into various cell types by a CMV vector.
Analyzing the range of target cells for a CMV vector is only one step in CMV vector development. Further steps are the determination of the cloning capacity of a CMV vector, the generation of replication-deficient vectors and finally construction of 'gutless' CMV amplicon vectors. With the establishment of the BAC cloning and mutagenesis system, these goals will now become feasible.
